Literature DB >> 1381908

Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

J P Langedijk1, N K Back, E Kinney-Thomas, C Bruck, M Francotte, J Goudsmit, R H Meloen.   

Abstract

Monoclonal antibodies raised against viral lysate of HIV-1 (strain LAV-1) and against recombinant gp 160 of HIV-1 (strain HTLV IIIB) which neutralized HIV-1 in a type specific manner were mapped with the aid of peptides (Pepscan analysis). Each of these monoclonal antibodies bound to peptides located on the principal neutralizing domain (PND) of HIV-1. We found that the antigenic sites of the MAbs described in this paper are represented by linear peptides of at least 10 amino acids long. The affinity of the MAbs is high for these peptides and in the same order of magnitude as for native gp 160. The fine mapping of the epitopes may reflect structural features of the PND, for instance which amino acid side chains are exposed and which are buried in the protein. Furthermore the fine mapping of the epitopes explained the HIV type-specific neutralizing activity of the MAbs. Antibodies that bound to the tip of the loop (amino acids QRGPGRAF) have a higher neutralizing activity than antibodies that bound to amino acids towards the N-terminal side of the loop (amino acids KSIRI). Furthermore, MAbs that bound to virtually the same amino acids on the tip of the loop (amino acids IQRGPGRAF and RGPGRAFV) had different neutralizing activities due to different affinities for native gp 160. These data reveal that neutralizing activity not only is determined by the affinity of an antibody to the neutralizing site but also by its fine binding specificities to the V 3 loop of gp 120.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381908     DOI: 10.1007/bf01309690

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  53 in total

1.  Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J P Langedijk; N K Back; P J Durda; J Goudsmit; R H Meloen
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

2.  A chink in HIV's armour?

Authors:  P E Stephens; G Clements; G T Yarranton; J Moore
Journal:  Nature       Date:  1990-01-18       Impact factor: 49.962

3.  Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.

Authors:  M Autiero; P Abrescia; M Dettin; C Di Bello; J Guardiola
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

Review 4.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

5.  Association of antibodies blocking HIV-1 gp 160-sCD4 attachment with virus neutralizing activity in human sera.

Authors:  N K Back; C Thiriart; A Delers; C Ramautarsing; C Bruck; J Goudsmit
Journal:  J Med Virol       Date:  1990-07       Impact factor: 2.327

6.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  A modified ELISA technique for anti-hapten antibodies.

Authors:  M Suter
Journal:  J Immunol Methods       Date:  1982-08-27       Impact factor: 2.303

9.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

Authors:  M A Skinner; R Ting; A J Langlois; K J Weinhold; H K Lyerly; K Javaherian; T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1988-06       Impact factor: 2.205

10.  HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.

Authors:  P J Durda; L Bacheler; P Clapham; A M Jenoski; B Leece; T J Matthews; A McKnight; R Pomerantz; M Rayner; K J Weinhold
Journal:  AIDS Res Hum Retroviruses       Date:  1990-09       Impact factor: 2.205

View more
  12 in total

1.  Posttranslational processing and identification of a neutralization domain of the GP4 protein encoded by ORF4 of Lelystad virus.

Authors:  J J Meulenberg; A P van Nieuwstadt; A van Essen-Zandbergen; J P Langeveld
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.

Authors:  J P Moore; A Trkola; B Korber; L J Boots; J A Kessler; F E McCutchan; J Mascola; D D Ho; J Robinson; A J Conley
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

4.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

6.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Authors:  J P Moore; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

7.  Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae.

Authors:  B Duim; L Vogel; W Puijk; H M Jansen; R H Meloen; J Dankert; L van Alphen
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

8.  Antigenic structure of the central conserved region of protein G of bovine respiratory syncytial virus.

Authors:  J P Langedijk; R H Meloen; G Taylor; J M Furze; J T van Oirschot
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.